NovoCure (NVCR) Net Cash Flow (2014 - 2026)

NovoCure (NVCR) has reported Net Cash Flow for 13 consecutive years, with $6.3 million the latest figure, recorded in Q2 2026.

• Quarterly Net Cash Flow fell 71.91% year-over-year to $6.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$48.3 million (down 188.04% YoY) and the FY2025 annual result came in at -$63.1 million, up 17.3% from the prior year.
• Net Cash Flow improved to $6.3 million in Q2 2026 per NVCR's latest filing, from -$5.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for NVCR reached as high as $214.9 million in Q1 2024 and fell as low as -$288.8 million in Q2 2024.
• A 5-year average of -$5.9 million and a median of -$3.4 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow jumped 2435.48% — and 2025, when it plunged 949.62%.
• Year by year, Net Cash Flow stood at -$128.4 million in 2022, then soared by 166.89% to $85.9 million in 2023, then plunged by 126.76% to -$23.0 million in 2024, then tumbled by 949.62% to -$241.2 million in 2025, then soared by 102.61% to $6.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $6.3 million, -$5.9 million, and -$241.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.